Akari Therapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AKTX and other ETFs, options, and stocks.

About AKTX

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor.

CEO

Abizer Gaslightwala

CEOAbizer Gaslightwala

Employees

Employees9

Headquarters

Boston, Massachusetts

HeadquartersBoston, Massachusetts

Founded

2004

Founded2004

Employees

Employees9

AKTX Key Statistics

Market cap

37.62M

Market cap37.62M

Price-Earnings ratio

-0.19

Price-Earnings ratio-0.19

Dividend yield

—

Dividend yield—

Average volume

10.36K

Average volume10.36K

High today

$1.30

High today$1.30

Low today

$1.25

Low today$1.25

Open price

$1.29

Open price$1.29

Volume

1.73K

Volume1.73K

52 Week high

$4.40

52 Week high$4.40

52 Week low

$0.85

52 Week low$0.85

Akari Therapeutics

Why Robinhood?

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. Show more

AKTX Key Statistics

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor.